New Delhi:Cancer patients affected with COVID-19 are twice as likely than the general patient population to die or become severely ill from the pandemic, said a recent study report of Lancet, the global medical journal.
The study led by the COVID-19 & Cancer Consortium (CCC19), which includes the Herbert Irving Comprehensive Cancer Centre (HICCC) also found that patients with cancer who have a higher fitness level and few underlying conditions can and should proceed with appropriate anti-cancer treatment.
"Those with poor fitness health or progressing cancer need to carefully consider-with their treating oncologist-whether the benefits outweigh the risk for continuing anti-cancer treatment during the COVID-19 pandemic," the study said.
The overall rate of complications for this cohort was high, regardless of whether the patients the had active cancer, were undergoing treatment for their cancer, or both. The ongoing study is being led by a consortium of more than 100 participating institutions and identified potential predictive factors for mortality and severe illness.
The researchers collected de-identified data on COVID-19 patients with active cancer or prior cancer, aged 18 years and older, from the period between March 17 and April 16, 2020. Data was generated from participating institutions in the US, Canada and Spain.
The study analysed data of 928 international cancer patients with COVID-19 and found the 30-day all-cause mortality was 13 per cent, more than double the mortality reported as the global average.